A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-23
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalation study of YH001 administered intravenously (IV) in
combination with Toripalimab. The study is designed to determine the safety, tolerability and
maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of YH001 when administered in
combination with Toripalimab to subjects with advanced solid tumors.